economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Production

US-listed company intends to make an offer to take over a minimum of 51% of the shares in DecideAct A/S and has signed LOI

US-listed company intends to make an offer to take over a minimum of 51% of the shares in DecideAct A/S and has signed LOI

creativebharatgroup@gmail.com November 14, 2024
DecideAct A/S [ACT] NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN DecideAct A/S (the Company) has signed...
Read More Read more about US-listed company intends to make an offer to take over a minimum of 51% of the shares in DecideAct A/S and has signed LOI
Tecnotree Selected to Provide Multi-Tenant MVNE Platform and Moments Marketplace to Power Tier 1 MVNE in EMEA OG_NewsReleaseCompanyLogo_92457.jpg

Tecnotree Selected to Provide Multi-Tenant MVNE Platform and Moments Marketplace to Power Tier 1 MVNE in EMEA

creativebharatgroup@gmail.com November 14, 2024
Espoo, Finland:   Tecnotree, a global digital Business Support Systems (BSS) provider and...
Read More Read more about Tecnotree Selected to Provide Multi-Tenant MVNE Platform and Moments Marketplace to Power Tier 1 MVNE in EMEA
2024 festive season sees highest gig workers demand driven by logistics, retail sectors: Report, ET Retail 115245335.cms

2024 festive season sees highest gig workers demand driven by logistics, retail sectors: Report, ET Retail

creativebharatgroup@gmail.com November 14, 2024
Gig workers Mumbai: Over 12 lakh gig or freelance roles were posted during the 2024 festive season,...
Read More Read more about 2024 festive season sees highest gig workers demand driven by logistics, retail sectors: Report, ET Retail
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen OG_Companylog_92449.jpg

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen

creativebharatgroup@gmail.com November 14, 2024
MUMBAI, India & HYDERABAD, India:  PopVax, an Indian full-stack biotechnology company developing novel...
Read More Read more about PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen